Metolazone withdrawal

We have recently learned from Sanofi-Aventis that they are shortly ceasing to manufacture and distribute metolazone. Metolazone is sometimes used for patients with heart failure and intractable fluid retention as an adjunct to loop diuretics as part of "sequential nephron blockade".

Most studies of combination therapy (loop+thiazide) have used metolazone, but Channer showed that metolazone and bendrofluazide were equally effective in inducing diuresis in patients with resistant oedema when added to intravenous frusemide.*

Our advice is to switch patients receiving metolazone to bendroflumethiazide when a patient's supplies run out, at a dose of 2.5 mg, increasing to 5mg, if indicated.

Generic manufacturers may step into the breach, and metolazone is likely to become available again in the UK in the future.

 

*Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994;71:146-150